TP53 mutations in myelodysplastic syndrome.

abstract：:This study investigated expression profiles of tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) pathway components and mechanisms underlying TRAIL-induced apoptosis in mucosa associated lymphoid tissue (MALT) lymphoma. Genetic aberrations including translocations and trisomies were assessed by rev...

journal_title：Leukemia & lymphoma

authors： Anees M,Horak P,Schiefer AI,Vaňhara P,El-Gazzar A,Perco P,Kiesewetter B,Müllauer L,Streubel B,Raderer M,Krainer M

更新日期：2015-05-01 00:00:00

abstract：:A recent phase III trial demonstrated improved progression-free survival (PFS) and overall survival (OS) associated with adding rituximab to fludarabine and cyclophosphamide (R-FC) compared to FC in treatment of previously untreated chronic lymphocytic leukemia (CLL). A cost-effectiveness analysis of R-FC over FC was ...

journal_title：Leukemia & lymphoma

authors： Hornberger J,Reyes C,Shewade A,Lerner S,Friedmann M,Han L,Gutierrez H,Satram-Hoang S,Keating MJ

更新日期：2012-02-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease with distinct biological and clinical features. The Philadelphia (Ph) chromosome and BCR/ABL fusion gene is the major cytogenetic and molecular marker of CML chronic phase. However, the molecular mechanisms of disease progression are not well known. R...

journal_title：Leukemia & lymphoma

authors： Zhang S

更新日期：2008-08-01 00:00:00

abstract：:Interferon-gamma (IFN-gamma) exhibits various properties including antigrowth activity in neoplastic and normal cells and regulatory roles in immune responses and hematopoiesis, but studies of IFN-gamma effects on human megakaryopoiesis have been inconclusive. Recently we have used serum-free culture of purified CD34+...

journal_title：Leukemia & lymphoma

authors： Tsuji K,Muraoka K,Nakahata T

更新日期：1998-09-01 00:00:00

abstract：:The aim of this study was to evaluate the frequency of polymorphisms in the TYMS, XRCC1, and ERCC2 DNA repair genes in pediatric patients with acute lymphoblastic leukemia using polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism (RFLP) approaches. The study was conducted in 206 patients a...

journal_title：Leukemia & lymphoma

authors： Canalle R,Silveira VS,Scrideli CA,Queiroz RG,Lopes LF,Tone LG

更新日期：2011-06-01 00:00:00

abstract：:All patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and treated over a 17-year period at a single institution were retrospectively analyzed. From 1990 to 2000, 40 patients were treated with a variety of adult-based ALL regimens. From 2000 to 2007, a pediatric-based protocol, DFCI (Dana Farber...

journal_title：Leukemia & lymphoma

authors： Al-Khabori M,Minden MD,Yee KW,Gupta V,Schimmer AD,Schuh AC,Xu W,Brandwein JM

更新日期：2010-01-01 00:00:00

abstract：:The aim of this study was to evaluate the influence of the most common genetic variants in methylenetetrahydrofolate reductase (MTHFR), thiopurine methyltransferase (TPMT) and glutathione-S-transferases (GSTs) on the outcome of acute lymphoblastic leukemia (ALL) treatment in Argentinean children. Two hundred and eight...

journal_title：Leukemia & lymphoma

authors： Aráoz HV,D'Aloi K,Foncuberta ME,Sanchez La Rosa CG,Alonso CN,Chertkoff L,Felice M

更新日期：2015-05-01 00:00:00

abstract：:We investigated the effect of rGM-CSF on the proliferation/differentiation balance of the leukemic cells maintained in liquid cultures during 7 days, from 16 patients with acute myelogenous leukemia (AML). Cell proliferation was measured by tritiated thymidine (3HT) incorporation, and by the plating efficiency (PE) ob...

journal_title：Leukemia & lymphoma

authors： Faussat-Suberville AM,Marie JP,Delmer A,Cadiou M,Zittoun R

更新日期：1993-09-01 00:00:00

abstract：UNLABELLED:We retrospectively analyzed the incidence of thrombotic and infectious complications in relation with the use of central venous catheters (CVCs), in a series of patients with hematological malignancies and low platelet and leucocyte counts. PATIENTS AND METHODS:126 patients with hematological malignancies w...

journal_title：Leukemia & lymphoma

authors： Cortelezzia A,Fracchiolla NS,Maisonneuve P,Moia M,Luchesini C,Ranzi ML,Monni P,Pasquini MC,Lambertenghi-Deliliers G

更新日期：2003-09-01 00:00:00

abstract：:We performed three different studies to obtain additional data on the biological and prognostic role of vascular endothelial growth factor C (VEGFC) in classical Hodgkin lymphoma (cHL): (1) serum VEGFC levels were measured by enzyme-linked immunosorbent assay in 80 patients; (2) immunohistochemical VEGFC expression in...

journal_title：Leukemia & lymphoma

authors： Rueda A,Olmos D,Vicioso L,Quero C,Gallego E,Pajares-Hachero BI,Mendiola M,Casanova M,Álvarez M,Provencio M,Alba E

更新日期：2015-05-01 00:00:00

abstract：:The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COV...

journal_title：Leukemia & lymphoma

authors： Tanasijevic AM,Revette A,Klepin HD,Zeidan A,Townsley D,DiNardo CD,Sebert M,DeZern AE,Stone RM,Magnavita ES,Chen R,Sekeres MA,Abel GA

更新日期：2020-12-01 00:00:00

abstract：:We have studied the effect of dimethyl-sulfoxide(DMSO)-induced granulocytic differentiation on the sensitivity of HL-60 cells to various cytotoxic topoisomerase II inhibitors: (i) undifferentiated HL-60 cells are highly sensitive to etoposide, while differentiated HL-60 cells are 700-1000 fold resistant to etoposide, ...

journal_title：Leukemia & lymphoma

authors： Gieseler F,Boege F,Biersack H,Spohn B,Clark M,Wilms K

更新日期：1991-01-01 00:00:00

abstract：:Mononuclear phagocytic cells and CD4+ T lymphocytes represent the major targets for infection by HIV-1 in vivo. The most severe pathogenic features associated with HIV-1 infection can be attributed to malfunction or premature death of these cells that are of hematopoietic origin. Patients with acquired immunodeficienc...

journal_title：Leukemia & lymphoma

authors： Kulkosky J,Bouhamdan M,Geist A,Nunnari G,Phinney DG,Pomerantz RJ

更新日期：2000-05-01 00:00:00

abstract：:Granulocytic sarcoma (chloroma) is a rare solid tumor resulting from the proliferation of myelogenous leukemia cells. Chloromas usually present as soft tissue or bony masses of the head and neck in patients with acute myelogenous leukemia (AML) of the French-American-British M2 subtype. Occasionally chloromas may occu...

journal_title：Leukemia & lymphoma

authors： Landis DM,Aboulafia DM

更新日期：2003-10-01 00:00:00

abstract：:The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the ...

journal_title：Leukemia & lymphoma

authors： Eghtedar A,Rodriguez I,Kantarjian H,O'Brien S,Daver N,Garcia-Manero G,Ferrajoli A,Kadia T,Pierce S,Cortes J,Ravandi F

更新日期：2015-05-01 00:00:00

abstract：:Richter's transformation (RT) refers to the development of an aggressive lymphoma in patients with chronic lymphocytic leukemia (CLL). Approximately, 2-10% of patients with CLL develop RT, most often as diffuse large B-cell lymphoma. To assess the incidence of RT, we examined risk factors for RT and death among patien...

journal_title：Leukemia & lymphoma

authors： Ben-Dali Y,Hleuhel MH,da Cunha-Bang C,Brieghel C,Poulsen CB,Clasen-Linde E,Bentzen HHN,Frederiksen H,Christiansen I,Nielsen LH,Enggaard L,Helleberg M,Clausen M,Frederiksen M,Pedersen RS,Niemann CU,Andersen MA

更新日期：2020-06-01 00:00:00

abstract：:We describe the patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the initial staging of patients with newly diagnosed grade 1-2 follicular lymphoma (FL) and its potential impact on treatment. Data were obtained from the National Comprehensive Cancer Network Non-Hodgkin Lymphoma...

journal_title：Leukemia & lymphoma

authors： Abou-Nassar KE,Vanderplas A,Friedberg JW,Abel GA,Niland J,Rodriguez MA,Czuczman MS,Millenson M,Crosby A,Gordon LI,Zelenetz AD,Kaminski M,Lacasce AS

更新日期：2013-10-01 00:00:00

abstract：:BRAF mutations have been shown to occur at a high frequency in melanoma and thyroid cancer, but also at lower frequencies in hematological malignancies. To assess the potential role of BRAF, we have sequenced exons 11 and 15 of BRAF in 138 cases with chronic lymphocytic leukemia (CLL) and 32 cases of B-cell prolymphoc...

journal_title：Leukemia & lymphoma

authors： Jebaraj BM,Kienle D,Bühler A,Winkler D,Döhner H,Stilgenbauer S,Zenz T

更新日期：2013-06-01 00:00:00

abstract：:Because of the lack of standard treatment in refractory and relapsed acute myelogenous leukemia (AML) several new drugs have been employed alone to evaluate their efficacy in this peculiar category of patient. Bisantrene, a new anthracene bishydrazone derivative, has shown antileukemic effect in phase I and II clinica...

journal_title：Leukemia & lymphoma

authors： Spadea A,Petti MC,Aloespiriti MA,Avvisati G,De Gregoris C,Fazi P,Latagliata R,Amadori S,Mandelli F

更新日期：1993-02-01 00:00:00

abstract：:The prognostic significance of rare BCR-ABL1 transcripts is uncertain in the tyrosine kinase inhibitor (TKI) era. In this retrospective study, 40 (1.7%) patients with rare BCR-ABL1 transcripts were identified from a cohort of 2331 chronic myeloid leukemia (CML) patients; 4 types of rare transcripts were identified, in...

journal_title：Leukemia & lymphoma

authors： Xue M,Wang Q,Huo L,Wen L,Yang X,Wu Q,Pan J,Cen J,Ruan C,Wu D,Chen S

更新日期：2019-12-01 00:00:00

abstract：:Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clinical phase I/II trials, blinatumomab showed remarkable single-agent a...

journal_title：Leukemia & lymphoma

authors： Goebeler ME,Bargou R

更新日期：2016-05-01 00:00:00

abstract：:Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/...

journal_title：Leukemia & lymphoma

authors： Schirren CA,Völpel H,Hoffmann JC,Henning SW,Qiao L,Autschbach F,Dengler TJ,Döhner H,Meuer SC

更新日期：1993-05-01 00:00:00

abstract：:Monoclonal proteins (paraproteins) may be detected in the sera in approximately 1% of the general population and are frequently associated with peripheral neuropathy. Paraproteinemic neuropathy (PPN) is most commonly associated with monoclonal gammopathy of undetermined significance, and may also occur in the context ...

journal_title：Leukemia & lymphoma

authors： Zivković SA,Lacomis D,Lentzsch S

更新日期：2009-09-01 00:00:00

abstract：:We investigated whether etoposide might be a suitable alternative to anthracyclins for the treatment of elderly patients with acute myeloid leukemia (AML) in whom anthracyclins are contraindicated. In total, 88 patients over 60 years old were treated in our department between 1988 and 2000 for de novo or secondary AML...

journal_title：Leukemia & lymphoma

authors： Chaoui D,Peffault De Latour R,Legrand O,Marie JP

更新日期：2005-03-01 00:00:00

abstract：:In the HOVON68 CLL trial, patients 65 to 75 years of age had no survival benefit from the addition of low-dose alemtuzumab to fludarabine and cyclophosphamide (FC) in contrast to younger patients. The reasons are explored in this 5-year trial update using both survival analysis and competing risk analysis on non-CLL-r...

journal_title：Leukemia & lymphoma

authors： Vojdeman FJ,Van't Veer MB,Tjønnfjord GE,Itälä-Remes M,Kimby E,Polliack A,Wu KL,Doorduijn JK,Alemayehu WG,Wittebol S,Kozak T,Walewski J,Abrahamse-Testroote MC,van Oers MH,Geisler CH

更新日期：2017-03-01 00:00:00

abstract：:Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated with second-line therapies. Resistan...

journal_title：Leukemia & lymphoma

authors： Sever M,Newberry KJ,Verstovsek S

更新日期：2014-12-01 00:00:00

abstract：:Abstract Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and...

journal_title：Leukemia & lymphoma

authors： Ram R,Storb R

更新日期：2013-08-01 00:00:00

abstract：:The aberrant expression of myeloid antigen CD66 on acute B-lymphoblastic leukemia (B-ALL) cells is a well-documented phenomenon. CD66a is a major subtype of the CD66 family which plays a dual role in different cancers, and the contradictory effect may depend on the isoform ratio of CD66a-4L to CD66a-4S. Although the a...

journal_title：Leukemia & lymphoma

authors： Zhao W,Zhang Y,Liu D,Zhong L,He Q,Zhao Y

更新日期：2015-01-01 00:00:00

abstract：:Since rising serum lactate dehydrogenase (LDH) heralds progression in patients with lymphoma or myeloma we investigated the significance of its elevations during chemotherapy supported by granulocyte (G-) or Granulocyte-Macrophage (GM-) colony stimulating factors (CSF). To Exclude effects of resistant disease we analy...

journal_title：Leukemia & lymphoma

authors： Sarris AH,Majlis A,Dimopoulos MA,Younes A,Swann F,Rodriguez MA,McLaughlin P,Cabanillas F

更新日期：1995-05-01 00:00:00

abstract：:Short responses to immunochemotherapy predict for an inferior OS in follicular lymphoma. We set out to determine whether this is also the case in marginal zone lymphoma. A group of 139 marginal zone lymphoma (MZL) patients treated with front-line immuno- or immunochemotherapy (I/ICT) were categorized into I/ICT-refrac...

journal_title：Leukemia & lymphoma

authors： Sorigue M,Bishton M,Domingo-Domenech E,McMillan A,Prusila R,García O,Kuusisto M,Condom M,Tapia G,Ribera JM,Kuittinen O,Fox CP,Sancho JM

更新日期：2019-10-01 00:00:00